HRZN Stock UPDATES Horizon Technology Finance Corp (HRZN) 14.36

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Horizon Technology Finance Corp (HRZN) 14.36 $HRZN

Best Of The Buy-Rated Dividend Stocks: Top 3 Companies: TCPC, HRZN, DOM
at The Street - Tue Sep 02, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

3 Buy-Rated Dividend Stocks: KCAP, SUNS, HRZN
at The Street - Mon Aug 25, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

3 Buy-Rated Dividend Stocks Taking The Lead: SUNS, HRZN, CODI
at The Street - Thu Aug 14, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

Tomorrow's Ex-Dividends To Watch: TSLF, HRZN, WWD
at The Street - Thu Aug 14, 9:05AM CDT
TSLF HRZN WWD are going ex-dividend tomorrow, Friday, August 15, 2014

Horizon Technology Finance Announces Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) (the "Company" or "Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity-backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today announced its financial results for the second quarter ended June 30, 2014.

Horizon Technology Finance Announces Monthly Distributions for October, November and December 2014 Totaling $0.345 Per Share
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) ("Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services and cleantech industries, announced today that its board of directors declared monthly cash distributions of $0.115 per share payable in each of October, November and December 2014. These monthly distributions, payable as set forth in the table below, total $0.345 per share. Including the monthly distributions declared in the third quarter of 2014, Horizon has declared $5.96 per share in cumulative distributions since its October 2010 initial public offering.

Buy-Rated Dividend Stocks In The Top 3: PDH, FGP, HRZN
at The Street - Mon Jul 28, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet

Horizon Technology Finance to Announce Second Quarter 2014 Financial Results
eTeligis - Tue Jul 22, 3:15PM CDT
FARMINGTON, CT, United States, via eTeligis Inc., 07/22/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) (the "Company" or "Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, announced today that it plans to release financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, after the close of market trading.

Dividend Watch: 3 Stocks Going Ex-Dividend Tomorrow: KSM, EDI, HRZN
at The Street - Wed Jul 16, 9:04AM CDT
KSM EDI HRZN are going ex-dividend tomorrow, Thursday, July 17, 2014, 4:00 AM ET

Horizon Technology Finance Provides Investment Portfolio Update for Second Quarter 2014
Marketwire - Wed Jul 09, 3:15PM CDT
Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today provided a portfolio update for the second quarter of 2014.

CORRECTING and REPLACING mBlox Raises Significant Capital to Accelerate Growth and Innovation
Business Wire - Wed Jul 09, 8:11AM CDT
Third paragraph, second sentence of release dated July 7, 2014, should read: Comerica and Horizon Technology Finance Corporation (Nasdaq: HRZN) were among the participants, in addition to some of mBlox's largest investors including Norwest Venture Partners, Scale Ventures, Avanti, Trident, Stratim and Saints Capital (instead of ...Stratem and Saints Capital).

Horizon Technology Finance Provides $6 Million Venture Loan Facility to SpringCM
eTeligis - Tue Jul 08, 3:21PM CDT
FARMINGTON, CT and CHICAGO, IL, United States, via eTeligis Inc., 07/08/2014 - - Horizon Technology Finance Corporation (NASDAQ:HRZN) (the "Company" or "Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it closed a $6 million venture loan facility with SpringCM Inc. ("SpringCM" , a leader in content cloud services. SpringCM will use the proceeds of the venture loan facility to support its continued growth.

Horizon Technology Finance Leads $25 Million Venture Loan to mBlox
eTeligis - Mon Jul 07, 3:15PM CDT
FARMINGTON, CT and ATLANTA, GA, United States, via eTeligis Inc., 07/07/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it led a $25 million venture loan for mBlox, Inc. ("mBlox" , the largest global provider of A2P (application-to-person) text messaging. The venture loan was fully funded at closing, with Horizon funding its commitment of $10 million. mBlox will use the funds to support its continued growth.

Horizon Technology Finance Closes $3 Million Venture Loan to GenePeeks
eTeligis - Mon Jun 30, 3:29PM CDT
FARMINGTON, CT and NEW YORK, NY, United States, via eTeligis Inc., 06/30/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, announced today it has closed a $3 million venture loan for GenePeeks, Inc. ("GenePeeks" , a genetic information company focused on reproductive risk prediction. GenePeeks will use the funds to support its continued growth.

Horizon Technology Finance Announces Prepayment and Termination of Term Loan Facility
Marketwire - Wed Jun 18, 1:32AM CDT
Horizon Technology Finance Corporation (NASDAQ: HRZN) (the "Company" or "Horizon" , a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, announced today the termination of its term loan credit facility ("Term Loan Facility" with Fortress Credit Co LLC, an affiliate of Fortress Investment Group LLC ("Fortress Credit" and the Company's prepayment of all outstanding amounts due thereunder. Horizon maintains borrowing capacity pursuant to its existing $50 million revolving credit facility (the "Key Facility" with Key Equipment Finance Inc. ("Key" which contains an accordion feature allowing for an increase in the total loan commitment up to an aggregate commitment of $150 million.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 183

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 437

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 221

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading